HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

Nicolás M. S. Gálvez; Yi Cao; Adam D. Nitido; Cailin E. Deal; Christine L. Boutros; Scott W. MacDonald; Yentli E. Soto Albrecht; Evan C. Lam; Maegan L. Sheehan; Dylan Parsons; Allen Z. Lin; Martin J. Deymier; Jacqueline M. Brady; Benjamin Moon; Christopher Bullock; Serah Tanno; Amarendra Pegu; Xuejun Chen; Cuiping Liu; Richard A. Koup; John R. Mascola; Vladimir Vrbanac; Daniel Lingwood; Alejandro B. Balazs

doi:10.1101/2024.07.11.603156

Cite This Study

Gálvez et al. (2024) studied this question.

synapsesocial.com/papers/68e6087cb6db64358759c2c6 https://doi.org/10.1101/2024.07.11.603156

View Full Paper

Ask AI

Bookmark

Abstract

Broadly neutralizing antibodies (bNAbs) have shown great promise for prevention and treatment of HIV infection. Breadth of bNAb neutralization, measured

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

Abstract

Discussion

Cite This Study

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

Abstract

Discussion

Cite This Study

Keep reading

Keep reading